目的 地尔硫艹（上）卓（下）(合心爽)临床Ⅱ期试验研究，观察合心爽对肿瘤病人放疗不良反应治疗效果，评价口服合心爽的抗辐射效果。方法 采用肿瘤病人下半身照射试验模型，观察病人⁶⁰Coγ射线放疗后临床症状、外周血白细胞和血小板数及外周血染色体畸变率。结果 合心爽明显降低22例放射治疗病人的食欲减退、腹泻、呕吐的发生率；与对照组比较，合心爽组的外周血白细胞总数和血小板总数在照射后30 d中总体水平上均有较好的恢复；染色体畸变率降低，按染色体畸变率估计，未治疗组患者全血的总平均吸收剂量为1.52 Gy，而合心爽给药组仅为0.86 Gy。结论 该实验条件下，口服合心爽能减轻肿瘤病人放疗不良反应的发生程度。

OBJECTIVE To study the radioprotective effect of orally administered Diltiazem in phase Ⅱ clinicaltrial METHODS The model of tumor patient radiated at the latter half of body was used. Clinical symptom, the count of WBC and PLT and radio of lymphocyte abnormal chromosome of patient were observed RESULTS Investigation on 22 patients receiving radiotherapy showed that Diltiazem reduced the side clinical symptom caused by irradiation. At day 1 through day 21, the counts of WBC and PLT of Diltiazem group had various degree of increase than irradiation and the difference between Diltiazem group and control group was significant at some time Dicentric yield of the Diltiazem group was lower than that of the control. According to the dicentric yield the estimated average absorbed dose of the total blood of the untreated patients was 1.52 Gy, Whereas that of the Diltiazem administered group was only 0.86 Gy CONCLUSION It can be assumed that Diltiazem can reduce the side effect of the tumor patient caused by irradiation under these experimental conditions.